OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Helen M. Colhoun, Ildiko Lingvay, Paul Brown, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 2058-2066
Open Access | Times Cited: 62
Helen M. Colhoun, Ildiko Lingvay, Paul Brown, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 2058-2066
Open Access | Times Cited: 62
Showing 26-50 of 62 citing articles:
Obesity‐related glomerulopathy: How it happens and future perspectives
Jian‐Wen Samuel Lee‐Boey, Juan Tan, Zi Yi Lim, et al.
Diabetic Medicine (2025)
Open Access
Jian‐Wen Samuel Lee‐Boey, Juan Tan, Zi Yi Lim, et al.
Diabetic Medicine (2025)
Open Access
GLP-1 receptor agonists and other incretin mimetics for diabetes and chronic kidney disease—a KDIGO commentary
Ian H. de Boer, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2025) Vol. 107, Iss. 5, pp. 767-771
Closed Access
Ian H. de Boer, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2025) Vol. 107, Iss. 5, pp. 767-771
Closed Access
Low-energy diets for obesity and CKD (SLOW-CKD randomized feasibility study)
Marguerite M. Conley, Hannah L. Mayr, Kirsten Hepburn, et al.
Kidney International Reports (2025)
Open Access
Marguerite M. Conley, Hannah L. Mayr, Kirsten Hepburn, et al.
Kidney International Reports (2025)
Open Access
The cardiology community begins to embrace obesity as an important target for cardiovascular health
Naveed Sattar, Martin K. Rutter
PLoS Medicine (2025) Vol. 22, Iss. 4, pp. e1004578-e1004578
Open Access
Naveed Sattar, Martin K. Rutter
PLoS Medicine (2025) Vol. 22, Iss. 4, pp. e1004578-e1004578
Open Access
GLP-1-based therapies for diabetes, obesity and beyond
Daniel J. Drucker
Nature Reviews Drug Discovery (2025)
Closed Access
Daniel J. Drucker
Nature Reviews Drug Discovery (2025)
Closed Access
INNOVATIVE THERAPEUTICS FOR RENOPROTECTION: WHERE WE ARE
Monica Cortinovis, Norberto Perico, Giuseppe Remuzzi
Pharmacological Reviews (2025), pp. 100060-100060
Closed Access
Monica Cortinovis, Norberto Perico, Giuseppe Remuzzi
Pharmacological Reviews (2025), pp. 100060-100060
Closed Access
Diabetic Kidney Disease — Semaglutide Flows into the Mainstream
William G. Herrington, Richard Haynes
New England Journal of Medicine (2024) Vol. 391, Iss. 2, pp. 178-179
Closed Access | Times Cited: 3
William G. Herrington, Richard Haynes
New England Journal of Medicine (2024) Vol. 391, Iss. 2, pp. 178-179
Closed Access | Times Cited: 3
Recent achievements and future directions of anti-obesity medications
Gerald Grandl, Aaron Novikoff, Xue Liu, et al.
The Lancet Regional Health - Europe (2024) Vol. 47, pp. 101100-101100
Open Access | Times Cited: 3
Gerald Grandl, Aaron Novikoff, Xue Liu, et al.
The Lancet Regional Health - Europe (2024) Vol. 47, pp. 101100-101100
Open Access | Times Cited: 3
Using Second-Generation Anti-Obesity Medications
Sarah H. Schmitz, Louis J. Aronne
Diabetes Spectrum (2024) Vol. 37, Iss. 4, pp. 303-312
Closed Access | Times Cited: 3
Sarah H. Schmitz, Louis J. Aronne
Diabetes Spectrum (2024) Vol. 37, Iss. 4, pp. 303-312
Closed Access | Times Cited: 3
Long-term Outcomes of Lupus Nephritis in Comparison to Other CKD Etiologies
Charikleia Chrysostomou, Francesca Faustini, Iva Gunnarsson, et al.
Kidney International Reports (2024) Vol. 10, Iss. 1, pp. 157-168
Open Access | Times Cited: 2
Charikleia Chrysostomou, Francesca Faustini, Iva Gunnarsson, et al.
Kidney International Reports (2024) Vol. 10, Iss. 1, pp. 157-168
Open Access | Times Cited: 2
Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database
Jianxing Zhou, Wei Huang, Y. Xie, et al.
Endocrine (2024)
Closed Access | Times Cited: 2
Jianxing Zhou, Wei Huang, Y. Xie, et al.
Endocrine (2024)
Closed Access | Times Cited: 2
What the SELECT trial of semaglutide means for clinicians
Naveed Sattar, Matthew M.Y. Lee, Darren K. McGuire
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 1830-1831
Closed Access | Times Cited: 2
Naveed Sattar, Matthew M.Y. Lee, Darren K. McGuire
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 1830-1831
Closed Access | Times Cited: 2
Opportunities to optimize lifestyle interventions in combination with glucagon‐like peptide ‐1‐based therapy
Satya Dash
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S4, pp. 3-15
Open Access | Times Cited: 2
Satya Dash
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S4, pp. 3-15
Open Access | Times Cited: 2
GLP-1 Agonism for Kidney Transplant Recipients: A Narrative Review of Current Evidence and Future Directions Across the Research Spectrum
Victoria J. Riehl-Tonn, Kyle D. Medak, Christie Rampersad, et al.
Canadian Journal of Kidney Health and Disease (2024) Vol. 11
Open Access | Times Cited: 2
Victoria J. Riehl-Tonn, Kyle D. Medak, Christie Rampersad, et al.
Canadian Journal of Kidney Health and Disease (2024) Vol. 11
Open Access | Times Cited: 2
GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
Daria Abasheva, Alberto Ortíz, Beatriz Fernández‐Fernández
Clinical Kidney Journal (2024) Vol. 17, Iss. Supplement_2, pp. 19-35
Open Access | Times Cited: 2
Daria Abasheva, Alberto Ortíz, Beatriz Fernández‐Fernández
Clinical Kidney Journal (2024) Vol. 17, Iss. Supplement_2, pp. 19-35
Open Access | Times Cited: 2
Weekly Journal Scan: improved renal outcomes by semaglutide in patients with chronic kidney disease and type 2 diabetes in FLOW trial
Daniela Pedicino, Massimo Volpe
European Heart Journal (2024) Vol. 45, Iss. 38, pp. 3910-3911
Closed Access | Times Cited: 1
Daniela Pedicino, Massimo Volpe
European Heart Journal (2024) Vol. 45, Iss. 38, pp. 3910-3911
Closed Access | Times Cited: 1
The GLP-1 receptor agonist revolution comes to nephrology
Merlin C. Thomas, Mark E. Cooper
Nature Reviews Nephrology (2024) Vol. 20, Iss. 10, pp. 637-638
Closed Access | Times Cited: 1
Merlin C. Thomas, Mark E. Cooper
Nature Reviews Nephrology (2024) Vol. 20, Iss. 10, pp. 637-638
Closed Access | Times Cited: 1
Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide
Dario Giugliano, Katherine Esposito, Luca De Nicola
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 11, pp. 4813-4815
Closed Access | Times Cited: 1
Dario Giugliano, Katherine Esposito, Luca De Nicola
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 11, pp. 4813-4815
Closed Access | Times Cited: 1
Metabolically “extremely unhealthy” obese and non-obese people with diabetes and the risk of cardiovascular adverse events: the Silesia Diabetes - Heart Project
Oliwia Janota, Marta Sílvia Maria Mantovani, Hanna Kwiendacz, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Oliwia Janota, Marta Sílvia Maria Mantovani, Hanna Kwiendacz, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Glucagon-Like Peptide-1 Receptor Agonists: New Evidence of Kidney and Cardiovascular Protection From the FLOW and SELECT Trials
Maarten W. Taal, Nicholas M. Selby
American Journal of Kidney Diseases (2024)
Closed Access | Times Cited: 1
Maarten W. Taal, Nicholas M. Selby
American Journal of Kidney Diseases (2024)
Closed Access | Times Cited: 1
How Would You Manage This Patient With Obesity? Grand Rounds Discussion From Beth Israel Deaconess Medical Center
Risa B. Burns, Melanie Jay, Anne N. Thorndike, et al.
Annals of Internal Medicine (2024) Vol. 177, Iss. 10, pp. 1415-1424
Closed Access | Times Cited: 1
Risa B. Burns, Melanie Jay, Anne N. Thorndike, et al.
Annals of Internal Medicine (2024) Vol. 177, Iss. 10, pp. 1415-1424
Closed Access | Times Cited: 1
The Impact of Glucagon-like Peptide-1 Receptor Agonists on Kidney Outcomes: A Meta-Analysis of Randomized Placebo-Controlled Trials
Luís Mendonça, H. B. Moura, Paulo Castro‐Chaves, et al.
Clinical Journal of the American Society of Nephrology (2024)
Closed Access | Times Cited: 1
Luís Mendonça, H. B. Moura, Paulo Castro‐Chaves, et al.
Clinical Journal of the American Society of Nephrology (2024)
Closed Access | Times Cited: 1
Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
Rodrigo O. Moreira, Cynthia Melissa Valério, Alexandre Hohl, et al.
Archives of Endocrinology and Metabolism (2024) Vol. 68
Open Access | Times Cited: 1
Rodrigo O. Moreira, Cynthia Melissa Valério, Alexandre Hohl, et al.
Archives of Endocrinology and Metabolism (2024) Vol. 68
Open Access | Times Cited: 1
Tirzepatide for overweight and obesity management
Malak Hamza, Dimitris Papamargaritis, Melanie J. Davies
Expert Opinion on Pharmacotherapy (2024), pp. 1-19
Open Access | Times Cited: 1
Malak Hamza, Dimitris Papamargaritis, Melanie J. Davies
Expert Opinion on Pharmacotherapy (2024), pp. 1-19
Open Access | Times Cited: 1
Contemporary treatment patterns of overweight and obesity: insights from the Mass General Brigham health care system
John W. Ostrominski, Kavishwar B. Wagholikar, Kelly Olsson, et al.
Obesity (2024)
Open Access | Times Cited: 1
John W. Ostrominski, Kavishwar B. Wagholikar, Kelly Olsson, et al.
Obesity (2024)
Open Access | Times Cited: 1
